White Blood Cell Infusions to Treat HIV Infection
NCT00001647 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2008-03-04
Summary
This study will evaluate the safety and immune system effects of infusing HIV-infected patients with multiple doses of lymphocytes (white blood cells) from their non-infected identical twin. It will determine whether the donated lymphocytes can improve immune function and reduce viral load in the infected twin.
Identical twin pairs-one who is infected with HIV-1 and one who is negative for the virus-may be eligible for this study. Candidates will be screened with blood tests, a medical history and physical examination.
Both twin participants will receive a tetanus booster shot, if needed. The non-infected twin will undergo apheresis to collect white blood cells. For this procedure, whole blood is collected, similar to the procedure for donating a unit of blood from a needle in the arm. The blood flows through a cell separator machine where the white cells are removed, and the rest of the blood (red cells, plasma and platelets) is returned to the donor through a catheter in the opposite arm.
The collected lymphocytes will be given intravenously (through a vein) to the infected twin over a 60-minute period. This procedure-apheresis and infusions-will be repeated 4 days a week to complete one cycle. The cycles will be repeated about every 8 weeks for 6 cycles (about 1 year).
The infected twin will have blood samples drawn on the first day of each cycle, 2 weeks after the beginning of each cycle, and 4 weeks after each cycle to evaluate immune status, viral load and other safety parameters. The frequency of these blood tests may change as the study progresses. The infected twin will also undergo apheresis immediately before each cycle of infusions and one month later to test the white cells for certain immune features. The number of apheresis procedures may be reduced as the study proceeds.
Conditions
- Acquired Immunodeficiency Syndrome
- HIV Infection
Interventions
- PROCEDURE
-
White blood cell infusion
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Study Design
- Purpose
- TREATMENT
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1997-08-31
- Completion
- 2002-08-31
Countries
- United States
Study Locations
More Related Trials
-
Twins Study of Gene Therapy for HIV Infection
NCT00001535 ·Status: COMPLETED ·Phase: PHASE1
-
Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins
NCT01054872 ·Status: COMPLETED ·Phase: PHASE1
-
Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2
NCT03346499 ·Status: COMPLETED ·Phase: PHASE1
-
An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection
NCT00000647 ·Status: COMPLETED ·Phase: NA
-
Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors
NCT00029445 ·Status: RECRUITING
-
Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers
NCT00027482 ·Status: COMPLETED
-
H1N1 Vaccine at Two Dose Levels in HIV Positive Adults
NCT00992433 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients
NCT00001474 ·Status: COMPLETED ·Phase: PHASE2
-
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
NCT00039689 ·Status: RECRUITING
-
Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients
NCT00001357 ·Status: COMPLETED ·Phase: PHASE2
-
Adoptive Transfer of Haploidentical NK Cells and N-803
NCT03899480 ·Status: COMPLETED ·Phase: PHASE1
-
Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs
NCT00099671 ·Status: COMPLETED ·Phase: PHASE1
-
The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine
NCT00001112 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children
NCT00000827 ·Status: COMPLETED ·Phase: PHASE1
-
Immune Responses to Two Experimental HIV Vaccines in Healthy Adults
NCT01386489 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
NCT02165267 ·Status: COMPLETED ·Phase: PHASE1
-
Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection
NCT00000875 ·Status: TERMINATED ·Phase: NA
-
Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3
NCT00000756 ·Status: COMPLETED ·Phase: PHASE1
-
Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults
NCT00415649 ·Status: WITHDRAWN ·Phase: PHASE2
-
Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies
NCT00311688 ·Status: COMPLETED
-
Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection
NCT00002441 ·Status: COMPLETED ·Phase: PHASE3
-
Vaccine Treatment for HIV-Infection
NCT00108654 ·Status: COMPLETED ·Phase: PHASE1
-
Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
NCT02474901 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults
NCT01266616 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy
NCT00002449 ·Status: UNKNOWN ·Phase: PHASE1